Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
NCT03728972Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Nov 2018
- Primary completion
- Jun 2025
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Drugs
- pembrolizumab
- Conditions
- Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
01
Overview
Phase 2, open-label trial of pembrolizumab in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Response Rate up to 2 years. Started Nov 2018; status: active, not recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)
Pembrolizumab 200mg IVPB every 3 weeks
Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)
Pembrolizumab 200mg IVPB every 3 weeks
03
Who it enrols
Adults with untreated extranodal NK/T-cell lymphoma, nasal type, ECOG <= 1, adequate organ function, no prior treatment, no active autoimmune disease, no HIV/Hep B/Hep C.
04
Endpoints
Primary
Complete Response Rate
Beyond the preview
Go deeper on NCT03728972.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728972.